Clinical Research Directory
Browse clinical research sites, groups, and studies.
Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
Sponsor: London School of Economics and Political Science
Summary
This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate different sources of uncertainty about the benefits and harms of new cancer drugs on participants' decisions and understanding.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
3000
Start Date
2025-05-09
Completion Date
2025-06
Last Updated
2025-05-30
Healthy Volunteers
Yes
Conditions
Interventions
Statement communicating uncertainty with a single arm trial
Because Zenova has not been compared to other treatments, it is unknown if Zenova is better, the same, or worse than other treatments for non-small cell lung cancer.
Statement communicating uncertainty with limited study duration
Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown.
Statement communicating uncertainty with a limited study population
Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.
Statement communicating uncertainty with an unvalidated surrogate endpoint
Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.
Statement communicating uncertainty with treatment effect size
It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
Locations (1)
Harvard Medical School and Harvard Pilgrim Health Care Institute
Boston, Massachusetts, United States